1 mpared with the other groups (P </= .001 for
main outcome measure).
2 nalysis with arterial input function was the
main outcome measure.
3 within the first 28 days after birth) as the
main outcome measure.
4 n (control group) using daytime PaCO2 as the
main outcome measure.
5 the first year of clinical position was the
main outcome measure.
6 no other RRD surgery within 90 days, is the
main outcome measure.
7 ted for glass and acrylic prisms and was the
main outcome measure.
8 was created to estimate odds ratios for the
main outcome measures.
9 nimally important differences (MID) were the
main outcome measures.
10 en expression, and CEC density served as the
main outcome measures.
11 orrelation between different areas served as
main outcome measures.
12 PET/CT findings and mortality served as the
main outcome measures.
13 GPA and development of systemic GPA were the
main outcome measures.
14 o a retest control that did not complete the
main outcome measures;
16 participants provided no state
15 ve network growth were assessed as well as 2
main outcome measures:
accuracy during the Penn Continuo
16 MG; observation procedure(s): chart review;
main outcome measures:
anatomy, intraocular pressure (IO
17 Statistics and thresholds related to the
main outcome measures and potential moderators were inde
18 erviewer-rated PTSD symptom severity was the
main outcome measure,
and depression, anxiety, and funct
19 Incident all-cause dementia was the
main outcome measure,
and single- and dual-task gait vel
20 The
main outcome measures are cataract surgery-related compl
21 The
main outcome measures are reproducible, data-driven, cli
22 validated training anaphylaxis situation as
main outcome measures as well as secondary psychological
23 Main outcome measures assessed every 6 mo included the t
24 curity of maternal-infant attachment was the
main outcome measured at infant age 18 mo.
25 d untreated orbit was observed in any of the
main outcome measures at 6 months.
26 linical features and outcomes were gathered.
Main Outcome Measures:
Clinical setting, surgical techni
27 Main outcome measures consisted of ocular and systemic f
28 We identified ten
main outcome measure domains for amblyopia, 14 for strab
29 Main Outcome Measure:
Epidemiologic, clinical, OCT, AVF,
30 Suicidal ideation was the
main outcome, measured first by the Scale for Suicide Id
31 The
main outcome measure for the clinical study was insulin
32 Our
main outcome measures for comparison between groups were
33 Main outcome measures for the economic evaluation were t
34 Main outcome measures include (1) volume of total, new,
35 Main outcome measures include proportion of eye care pro
36 Main outcome measures included 1) One-year total length
37 Main outcome measures included best-corrected visual acu
38 Main outcome measures included clinical features, propor
39 Main outcome measures included degree of blood displacem
40 Main outcome measures included demographics, perioperati
41 Main outcome measures included device exposure and intra
42 Main outcome measures included functional and morphologi
43 Main outcome measures included incidence rates of vision
44 Main outcome measures included intraoperative handling,
45 The
main outcome measures included IOL decentration and PCO.
46 The
main outcome measures included logMAR best-corrected vis
47 Main outcome measures included mean change in BCVA in Ea
48 Main outcome measures included MMP Disease Area Index, F
49 The
main outcome measures included NK healing, corneal sensi
50 Main outcome measures included number of reoperations, s
51 Main outcome measures included participant's decision to
52 Main outcome measures included rates of visual loss and
53 Main outcome measures included resolution of serous reti
54 Main outcome measures included safety (rate of treatment
55 Main outcome measures included serious morbidity, in-hos
56 Our
main outcome measures included the cumulative incidence
57 Main outcome measures included the prevalence of catarac
58 The
main outcome measures included uncorrected (UDVA) and co
59 Main outcome measures included visual acuity improvement
60 Main outcome measures included visual acuity, Foster sta
61 Main outcomes measured included S(I) and glucose effecti
62 Physician demographic data were used as the
main outcome measures,
including length of experience, s
63 The
main outcome measures investigated were preterm delivery
64 Main outcome measure is consistency of ophthalmic outcom
65 The
main outcome measure is the change in intrapatient varia
66 Main outcome measure is the recovery of efferent dysfunc
67 Data including the
main outcome measure of mean difference in weight change
68 The
main outcome measures of the study were CSS and OS.
69 Main outcome measures Preference and willingness to pay
70 Correlations between
main outcome measures (
RPC density, NFL thickness, and v
71 MAIN OUTCOME MEASURE(
S): Annual incidence of late AMD, G
72 MAIN OUTCOME MEASURE(
S): At 3 months postoperatively, UC
73 MAIN OUTCOME MEASURE(
S): Five-item physical frailty inde
74 MAIN OUTCOME MEASURE(
S): Population-based CT/MR imaging
75 MAIN OUTCOME MEASURE(
S): Three-months-postoperative mono
76 MAIN OUTCOME MEASURE(
S): Treatment efficacy and side eff
77 MAIN OUTCOME MEASURE(
S): Visual acuity.
78 e diaminobenzidine chromogen and QIF was the
main outcome measure selected prior to performing the st
79 The
main outcome measure studied was final best-corrected vi
80 MAIN OUTCOMES MEASURES:
The primary objective was to sho
81 The
main outcome measure was 6-month postoperative IOP chang
82 The
main outcome measure was a diagnosis of PD.
83 The
main outcome measure was all-cause death.
84 The
main outcome measure was any albuminuria including both
85 The
main outcome measure was area of fluorescein leakage.
86 The
main outcome measure was area under the curve (AUC) of r
87 Main outcome measure was cases of FK per year.
88 Our
main outcome measure was change from month 6 to month 12
89 The
main outcome measure was change in amblyopic eye VA from
90 Main outcome measure was change in AOD750 after LPI.
91 The
main outcome measure was change in infection rates from
92 The
main outcome measure was choroidal thickness.
93 The
main outcome measure was clinical stabilization of kerat
94 The
main outcome measure was CVI, defined as the ratio of LA
95 Main outcome measure was final anatomic status.
96 Main outcome measure was final BCVA.
97 The
main outcome measure was final logMAR VA after bleb revi
98 Our
main outcome measure was fractional anisotropy (FA), a m
99 The
main outcome measure was freedom from recurrent biliary
100 The
main outcome measure was frequency of PCR positivity.
101 The
main outcome measure was globe salvage rate.
102 Main outcome measure was graft survival up to 5 years fo
103 The
main outcome measure was graft survival.
104 Our
main outcome measure was heightened regret as measured b
105 The
main outcome measure was hospital-acquired pneumonia, de
106 The
main outcome measure was incidence of presumed infectiou
107 Main outcome measure was incidence of RRD.
108 The
main outcome measure was incidence of unexpected managem
109 Our
main outcome measure was incident CVD (myocardial infarc
110 Main outcome measure was mean initial fluid-free interva
111 The
main outcome measure was mean intensity of nystagmus at
112 The
main outcome measure was mean participant scores at the
113 Main outcome measure was median percent adherence over 3
114 The
main outcome measure was mortality rate ratios (MRRs): d
115 Main outcome measure was mortality.
116 The
main outcome measure was patient refusal of fellow eye s
117 The
main outcome measure was percentage of cases achieving a
118 The
main outcome measure was plug retention at 6 months.
119 The
main outcome measure was pooled proportion of missed and
120 The
main outcome measure was positive growth on cultured med
121 The
main outcome measure was post-discharge opioid consumpti
122 The
main outcome measure was postoperative complications aft
123 The
main outcome measure was prediction error at 7 years of
124 The
main outcome measure was prediction of glaucomatous VF d
125 The
main outcome measure was recurrence of GERD, which was d
126 Main Outcomes and Measures: The
main outcome measure was relapse of psychosis, defined a
127 The
main outcome measure was riboflavin concentration at the
128 The
main outcome measure was risk-adjusted odds of all-cause
129 The
main outcome measure was SLT success (defined as IOP </=
130 The
main outcome measure was SSI during the first 60 days af
131 Main outcome measure was success rate, defined as intrao
132 The
main outcome measure was surgical failure, defined as pa
133 Main outcome measure was the annual incidence and preval
134 The
main outcome measure was the central macular ChT (0.5-mm
135 aseline were recorded at each visit, and the
main outcome measure was the clinical response to topica
136 The
main outcome measure was the diagnosis of macular edema
137 Our
main outcome measure was the difference in the proportio
138 The
main outcome measure was the first recurrence of syncope
139 The
main outcome measure was the grade of scrolling of PDEK
140 Main outcome measure was the identification of abnormal
141 The
main outcome measure was the identification of the FAF p
142 The
main outcome measure was the incremental cost per DALY a
143 The
main outcome measure was the involvement of the PDL in D
144 The
main outcome measure was the likelihood of association b
145 The
main outcome measure was the odds of discharge within 6
146 The
main outcome measure was the odds of endophthalmitis usi
147 The
main outcome measure was the odds ratio of diabetes per
148 The
main outcome measure was the prevalence of moderate-to-s
149 The
main outcome measure was the proportion of infants with
150 The
main outcome measure was the relative utilization of ret
151 Main outcome measure was the retention of the capsular b
152 The
main outcome measure was the risk ratio (RR) for major v
153 The
main outcome measure was the Rivermead Post-Concussion Q
154 The
main outcome measure was the use of anticoagulants (vita
155 The
main outcome measure was time to complete corneal epithe
156 The
main outcome measure was total gray matter [(11)C]PBR28
157 Main outcome measure was VA.
158 The
main outcome measure was vascular access site complicati
159 The
main outcome measure was vision-related functional burde
160 The
main outcome measure was whether or not postoperative do
161 The
main outcomes measure was presence of 1 or more postoper
162 The
main outcome measures were (1) the proportion of LTs per
163 The
main outcome measures were 1) mood, which was assessed b
164 Main outcome measures were 1) occurrence of repeated ker
165 The
main outcome measures were 90-day mortality and independ
166 The
main outcome measures were AC depth in the diseased eye
167 The
main outcome measures were all-cause mortality and the T
168 The
main outcome measures were as follows.
169 The
main outcome measures were asthma and rhinitis symptoms,
170 Main outcome measures were asthma-related hospitalizatio
171 Main outcome measures were average and minimum values of
172 Main outcome measures were average retinal/choroidal thi
173 The
main outcome measures were baseline NEI VFQ-25 composite
174 Main outcome measures were BCVA gain of 15 or more ETDRS
175 Our
main outcome measures were best spectacle-corrected visu
176 Main outcome measures were best-corrected visual acuity
177 The
main outcome measures were best-corrected visual acuity
178 Main outcome measures were best-corrected visual acuity
179 Main outcome measures were best-corrected visual acuity
180 The
main outcome measures were best-corrected visual acuity
181 The
main outcome measures were best-corrected visual acuity,
182 The
main outcome measures were bulimic symptoms assessed by
183 Main outcome measures were CCT (mum) and its association
184 The
main outcome measures were change from baseline best-cor
185 The
main outcome measures were change in the percentage of t
186 Main outcome measures were change in visual acuity and t
187 Main outcome measures were change in visual acuity, macu
188 The
main outcome measures were change in weight and body mas
189 Main outcome measures were changes from central gaze in
190 The
main outcome measures were changes in BCVA and CMT.
191 The
main outcome measures were changes in choroidal maps aft
192 The
main outcome measures were ciTBIs (resulting in death, n
193 Main outcome measures were clinical and histological cle
194 Main outcome measures were clinical and radiological fin
195 The
main outcome measures were complete success rates at 24
196 The
main outcome measures were control of ocular inflammatio
197 Main outcome measures were corrected distance visual acu
198 The
main outcome measures were correlation between percentag
199 Main outcome measures were correlations between central
200 biopsy-verified IgAN diagnosed in 1974-2011;
main outcome measures were death and ESRD.
201 The
main outcome measures were diabetes (fasting plasma gluc
202 The
main outcome measures were final visual outcomes and fac
203 Our
main outcome measures were frontal midline theta activit
204 Main outcome measures were graft preparation and unfoldi
205 Main outcome measures were graft rejection or failure at
206 Main outcome measures were graft survival, BCVA, refract
207 Main outcome measures were hazard ratios (HRs) for post-
208 The
main outcome measures were heart rate, breathing rate, p
209 The
main outcome measures were hospital records of pain, fat
210 The
main outcome measures were incidence of graft infection,
211 Main outcome measures were incidence of Killip class >=I
212 Main outcome measures were incidence of unexpected manag
213 Main outcome measures were incidence or progression of D
214 The
main outcome measures were incidence, risk factors, pred
215 Main outcome measures were incremental areas under the c
216 The
main outcome measures were intervention uptake, change i
217 Main outcome measures were intra- and inter-observer agr
218 Main outcome measures were intraoperative and postoperat
219 The
main outcome measures were intraoperative capsule compli
220 The
main outcome measures were IOP reduction at 6 and 12 mon
221 The
main outcome measures were lipopolysaccharide-stimulated
222 The
main outcome measures were major 1-year CVD complication
223 Main outcome measures were mean IAIs given through month
224 Main outcome measures were mean prediction errors with H
225 Main outcome measures were mean RNFL thickness and perip
226 The
main outcome measures were median height for age and bod
227 The
main outcome measures were mobility, square localization
228 The
main outcome measures were monocular and binocular uncor
229 The
main outcome measures were morphologic features of choro
230 The
main outcome measures were mortality and unfavourable fu
231 Our
main outcome measures were mortality, complications, and
232 The
main outcome measures were new diagnoses of type 2 diabe
233 Main outcome measures were number of clinic visits, diag
234 Main outcome measures were OSDI and tear osmolarity.
235 Main outcome measures were overall and disease-specific
236 Main outcome measures were overall survival (OS), define
237 The
main outcome measures were pain due to the ulcer, ulcer
238 The
main outcome measures were perinatal history, visual and
239 The
main outcome measures were postoperative best-corrected
240 Main outcome measures were postoperative intraocular pre
241 The
main outcome measures were postoperative surgical outcom
242 The
main outcome measures were presenting symptoms, types of
243 Main outcome measures were previous IOL exchange or repo
244 Main outcome measures were proportion of eyes at 1-year
245 Main outcome measures were quality of life (operationali
246 The
main outcome measures were rates of preamputation arteri
247 The
main outcome measures were refractive error, visual acui
248 Main outcome measures were regional En/DMT and TCT.
249 The
main outcome measures were resolution of infection, fina
250 The
main outcome measures were risk of postpartum AD, durati
251 The
main outcome measures were safety, immunologic response,
252 Main outcome measures were safety, including treatment-e
253 The
main outcome measures were sensitivity, specificity, and
254 Our
main outcome measures were sensitivity, specificity, pos
255 Main outcome measures were sleep onset latency (SOL), wa
256 Main outcome measures were spending by Medicare as track
257 The
main outcome measures were success (sample that gave a s
258 The
main outcome measures were success rate in performing hy
259 The
main outcome measures were surgical success rate and the
260 The
main outcome measures were survival and discharge home.
261 Main outcome measures were symptom scores and disease-sp
262 Main outcome measures were symptoms and signs of dry eye
263 Main outcome measures were the association of IVF sensit
264 The
main outcome measures were the data obtained per disease
265 Main outcome measures were the development of ROP and th
266 Main outcome measures were the DRF symptoms of irritabil
267 The
main outcome measures were the frequency and interconnec
268 The
main outcome measures were the frequency of and risk fac
269 Our
main outcome measures were the frequency of trial noncom
270 The
main outcome measures were the incidence of clinical end
271 Main outcome measures were the incidence of elevated IOP
272 The
main outcome measures were the incidence of ocular remis
273 Main outcome measures were the incidences of HIT-specifi
274 Main outcome measures were the key clinical features, an
275 The
main outcome measures were the occurrence and severity o
276 Main outcome measures were the prevalence of localized R
277 The
main outcome measures were the prevalence of LS in an un
278 Main outcome measures were the prevalence of perforating
279 The
main outcome measures were the proportion of children de
280 Main outcome measures were the recognition of the FAF pa
281 The
main outcome measures were the sensitivity, specificity
282 Main outcome measures were the time to rubeosis, the tim
283 Main outcome measures were time to distant failure, loca
284 Main outcome measures were to evaluate the effect of DPD
285 Main outcome measures were tonographic outflow facility,
286 The
main outcome measures were total operative time, macular
287 For RCTs,
main outcome measures were treatment benefits in pCR and
288 The
main outcome measures were UCVA, BCVA, steep and flat si
289 The
main outcome measures were uncorrected distance visual a
290 The study's
main outcome measures were uncorrected visual acuity, st
291 Main Outcome Measures were visual acuity (VA), number of
292 The
main outcome measures were visual acuity at 3 months and
293 The
main outcome measures were visual acuity, HVF MD, and RN
294 The
main outcome measures were visual acuity, optical cohere
295 The
main outcome measures were: total number of drops, volum
296 The
main outcomes measured were final best-corrected visual
297 Main outcomes measured were the MH closure rate assessed
298 Main outcomes measured were visual acuity, endothelial c
299 The
main outcomes measures were birth before 37 weeks due to
300 Main outcomes measures were the reasons for ICRS removal